Efficacy of Calmmax Cream in the Management of Chronic Uremic Pruritus
Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Uraemic pruritus (UP) remains a frequent and distressing problem in patients with advanced
chronic kidney disease (CKD) and end-stage renal disease (ESRD).
Calmmax is a new topical cream that was introduced recently by Calmmax Pharma, an Israeli
pharmaceutical company developed a topical cream based on active plant extracts for treatment
of skin inflammation. We intend to conduct a prospective, double blind, placebo controlled,
randomized trial that will assess the therapeutic effect of Calmmax cream on UP in a cohort
of CKD and ESRD patients.